These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 11925842)

  • 1. [Drug therapy for patients with mood disorders].
    Nomura S
    Seishin Shinkeigaku Zasshi; 2001; 103(12):1041-5. PubMed ID: 11925842
    [No Abstract]   [Full Text] [Related]  

  • 2. [Investigation on the therapeutic effect of carbamazepine on the mood disorders in Japan].
    Okuma T
    Seishin Shinkeigaku Zasshi; 2005; 107(5):415-22. PubMed ID: 15981617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pseudo-schizophrenic forms of mood disorders].
    Verdoux H; Peyre F; Bourgeois M
    Ann Med Psychol (Paris); 1991 Oct; 149(8):649-56; discussion 656-7. PubMed ID: 1776720
    [No Abstract]   [Full Text] [Related]  

  • 4. [Therapy for mood disorders].
    Nomura S
    Seishin Shinkeigaku Zasshi; 2006; 108(11):1244-8. PubMed ID: 17375458
    [No Abstract]   [Full Text] [Related]  

  • 5. Increasing sophistication of the pharmacotherapy of mood disorders.
    Joffe RT
    J Psychiatry Neurosci; 2002 Mar; 27(2):89. PubMed ID: 11944509
    [No Abstract]   [Full Text] [Related]  

  • 6. Practical management of treatment-resistant affective disorders.
    Bridges PK; Hodgkiss AD; Malizia AL
    Br J Hosp Med; 1995 Nov 15-Dec 12; 54(10):501-6. PubMed ID: 8574492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prescribing medications for mood disorders.
    Lynch JS
    Adv Nurse Pract; 1998 Mar; 6(3):22-6. PubMed ID: 9582735
    [No Abstract]   [Full Text] [Related]  

  • 8. Affective disorders & "chemical dependence": lithium for alcohol and drug addiction? A clinical note.
    Flemenbaum A
    Dis Nerv Syst; 1974 Jun; 35(6):281-5. PubMed ID: 17894301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Merging the cognitive behavioral and psychopharmacological paradigms in comparative studies: controversies, issues, and some solutions.
    Gorman JM; Barlow DH; Ray S; Shear MK; Woods S
    Psychopharmacol Bull; 2001; 35(2):111-24. PubMed ID: 12397891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The rise and fall of mood stabilizers.
    Malhi GS; Goodwin GM
    Aust N Z J Psychiatry; 2007 Oct; 41(10):779-83. PubMed ID: 17828650
    [No Abstract]   [Full Text] [Related]  

  • 11. [A clinical study on combined lithium and carbamazepine treatment of major affective disorders].
    Chen CC; Ko WK
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1987 Mar; 3(3):176-81. PubMed ID: 3482282
    [No Abstract]   [Full Text] [Related]  

  • 12. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication.
    Parikh SV; Segal ZV; Grigoriadis S; Ravindran AV; Kennedy SH; Lam RW; Patten SB;
    J Affect Disord; 2009 Oct; 117 Suppl 1():S15-25. PubMed ID: 19682749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Mechanism and clinical effects of drugs for mood disorder].
    Nakagawa S; Koyama T
    Ryoikibetsu Shokogun Shirizu; 2003; (38):358-61. PubMed ID: 12877002
    [No Abstract]   [Full Text] [Related]  

  • 14. What does Star*D tell us about ECT?
    McCall WV
    J ECT; 2007 Mar; 23(1):1-2. PubMed ID: 17435561
    [No Abstract]   [Full Text] [Related]  

  • 15. Achieving abstinence by treating depression in the presence of substance-use disorders.
    Hesse M
    Addict Behav; 2004 Aug; 29(6):1137-41. PubMed ID: 15236814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving adherence in mood disorders: the struggle against relapse, recurrence and suicide risk.
    Pompili M; Serafini G; Del Casale A; Rigucci S; Innamorati M; Girardi P; Tatarelli R; Lester D
    Expert Rev Neurother; 2009 Jul; 9(7):985-1004. PubMed ID: 19589049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Further evidence for a possible association between serotonin transporter gene and lithium prophylaxis in mood disorders.
    Serretti A; Malitas PN; Mandelli L; Lorenzi C; Ploia C; Alevizos B; Nikolaou C; Boufidou F; Christodoulou GN; Smeraldi E
    Pharmacogenomics J; 2004; 4(4):267-73. PubMed ID: 15111989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Porphyria and psychiatric manifestations].
    Pérez Bravo A; Arias Bal M; Gastañaduy MJ; Gómez-Reino JL
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1995; 23(6):319-21. PubMed ID: 8585440
    [No Abstract]   [Full Text] [Related]  

  • 19. Advancing the treatment of mood and anxiety disorders: the first 10 years' experience with paroxetine.
    Nemeroff CB
    Psychopharmacol Bull; 2003; 37 Suppl 1():6-7. PubMed ID: 14566195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Maintenance treatment and relapse prophylaxis of depressive disorders].
    Nyhuis PW
    MMW Fortschr Med; 2006 Jan; 148(4):26-8, 30. PubMed ID: 16502796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.